Portal de investigación
High-dose-rate brachytherapy boost for prostate cancer: Analysis of dose-volume histogram parameters for predicting late, rectal toxicity
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Chicas-Sett, R
- Farga, D
- Perez-Calatayud, MJ
Grupos
Abstract
PURPOSE: To determine the significance of dose-volume histogram parameters for predicting late rectal toxicity (LRT) after single-fraction high-dose-rate brachytherapy (HDRBT) boost and external beam radiotherapy (EBRT) in prostate cancer. MATERIALS AND METHODS: Three hundred patients with intermediate- or high-risk prostate cancer were included between August 2010 and March 2015. Treatment comprised a single-fraction HDRBT boost of 15.0 Gy plus EBRT (46.0 Gy delivered in 23 fractions) or an HDRBT boost of 9.5 Gy plus EBRT (60.0 Gy delivered in 30 fractions) if the seminal vesicles were infiltrated using real-time transrectal ultrasound-based planning. LRT was evaluated every 3 months after the end of the combined treatment using the Common Terminology Criteria for Adverse Events, version 4.0. The minimum dose received by the most exposed 0.1 and 2.0 cm(3) volume of the rectum (D0.1 cc/D2cc) was analyzed by estimating the biologically equivalent rectal dose according to the recommendations of the Groupe Europeen de Curietherapie/European Society for Radiotherapy and Oncology and an ordinal regression analysis was performed. RESULTS: LRT was observed in 62 patients (20.7%) at a median followup of 33 (range, 2-68) months. Twenty patients (6.7%) developed grade 2 and 3 patients (1%) developed grade 3 LRT. A significant association was observed between D2cc and the probability of developing grade 1-3 LRT (p = 0.04). CONCLUSIONS: D2cc is associated with the occurrence of LRT in HDRBT-treated prostate cancer patients. The dose constraints proposed and recommended by experienced HDRBT centers must be investigated to determine the threshold dose through long-term and prospective studies. (C) 2017 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.
Datos de la publicación
- ISSN/ISSNe:
- 1538-4721, 1873-1449
- Tipo:
- Article
- Páginas:
- 511-517
- Factor de Impacto:
- 0,951 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
Brachytherapy ELSEVIER SCIENCE INC
Citas Recibidas en Web of Science: 7
Documentos
- No hay documentos
Filiaciones
Keywords
- Biologically equivalent dose; Dose-volume histogram parameter; High-dose-rate brachytherapy boost; Late rectal toxicity; Organ at risk; Prostate cancer
Proyectos asociados
INNOVATIVE APPROACH FOR SELF-MANAGEMENT AND SOCIAL WELFARE OF CYSTIC FIBROSIS PATIENTS IN EUROPE: DEVELOPMENT, VALIDATION AND IMPLEMENTATION OF A TELEMATICS TOOL. MyCyFAPP
Investigador Principal: CARMEN RIBES KONINCKX
643806_H2020-PHC-2014-single-stage-MyCyFApp . COMISION EUROPEA . 2015
MEDIDA DEL IMPACTO DE LA RADIOTERAPIA CON INTENCIÓN CURATIVA COMBINADA O NO CON TERAPIA HORMONAL SOBRE LA CALIDAD DE VIDA EN LA PRÁCTICA CLÍNICA EN EL CÁNCER DE PRÓSTATA LOCALIZADO. ESTUDIO VEPIC-ORT.
Investigador Principal: FRANCISCO JAVIER CELADA ÁLVAREZ
ONC-MA-1003 . 2016
ESTUDIO DESCRIPTIVO DEL PERFIL DEL PACIENTE CON CANCER DE PROSTATA EN CONSULTA DE ONCOLOGIA RADIOTERAPICA.
Investigador Principal: ALEJANDRO TORMO MICO
ONC-RT01-10 . 2011
ESTUDIO ALEATORIZADO MULTICÉNTRICO EN FASE III DE RADIOTERAPIA DE CORTA DURACIÓN SEGUIDA DE QUIMIOTERAPIA PREOPERATORIA DE LARGA DURACIÓN Y CIRUGÍA EN EL CÁNCER RECTAL PRIMARIO DE ALTO RIESGO EN COMPARACIÓN CON QUIMIORRADIOTERAPIA CONVENCIONAL Y CIRUGÍA Y OPTIMA QUIMIOTERAPIA ADYUVANTE.
Investigador Principal: JORGE APARICIO URTASUN
RAPIDO
ESTUDIO EPIDEMIOLÓGICO OBSERVACIONAL PROSPECTIVO DEL MANEJO DEL DOLOR EN PACIENTES ONCOLÓGICOS EN TRATAMIENTO RADIOTERÁPICO.
Investigador Principal: FRANCISCO JOSÉ MARTÍNEZ ARCELUS
GOR-ANA-2012-01
TRATAMIENTO RADIOTERÁPICO EN PACIENTES CON CÁNCER DE PRÓSTATA EN FUNCIÓN DEL NIVEL DE RIESGO CONFORME A LA PRÁCTICA CLÍNICA HABITUAL EN LOS SERVICIOS DE ONCOLOGÍA RADIOTERÁPICA ESPAÑOLES.
Investigador Principal: ERICA COLLADO BALLESTEROS
GIC-RAD-2013-01
ESTUDIO DE BRAQUITERAPIA ELECTRÓNICA PARA CARCINOMA CUTÁNEO BASOCELULAR.
Investigador Principal: JOSÉ PÉREZ CALATAYUD
BCCBRACHY
EFECTIVIDAD DE LOS NUEVOS TRATAMIENTOS PARA EL CÁNCER DE PRÓSTATA LOCALIZADO DE BAJO RIESGO.
Investigador Principal: ALEJANDRO TORMO MICO
TTOPRÓSTATA/OBS
Cita
Chicas R,Farga D,Perez MJ,Celada F,Roldan S,Fornes V,Ibanez B,Tormo A,Benlloch JM,Perez J. High-dose-rate brachytherapy boost for prostate cancer: Analysis of dose-volume histogram parameters for predicting late, rectal toxicity. Brachytherapy. 2017. 16. (3):p. 511-517. IF:2,227. (2).